Skip to content
WhatIsLCA
Updates

What's new

Content additions, new features, and corrections — updated regularly so you can follow what has changed on WhatIsLCA.

  1. Content

    Added a 2026 Lancet review as an overview reference

    • The “How Treatments Work” page now cites a peer-reviewed Lancet review (2026) of inherited retinal degenerations and their emerging gene, cell, optogenetic, and implant therapies — an authoritative overview covering all the approaches described.
  2. Improved

    Treatment diagrams now play automatically

    • On the “How Treatments Work” page, each mechanism’s steps advance on their own with a progress bar — and pause the moment you click, so you can explore at your own pace.
  3. New

    Report an error on any page, and an editorial-standards page

    • Every page now has a one-click way to report an inaccuracy — via a form (no account needed) or our public community repository.
    • A new “Editorial standards” page explains how we source, review, and keep content current.
    • Pages now show a medical-review status so you can see how thoroughly each has been checked.
  4. Content

    New LCA5 (lebercilin) gene-therapy results

    • Added one-year Phase 1/2 results for OPGx-001 (peer-reviewed, Molecular Therapy 2025), plus the 2026 ARVO pediatric-cohort and LCA5 natural-history data.
  5. Content

    ATSN-101 (GUCY2D / LCA1) 3-year durability

    • Added 3-year follow-up showing durable vision gains for the ATSN-101 gene therapy, reported at the 2026 ARVO meeting.
  6. New

    “How Treatments Work” — an interactive 3D explainer

    • A new page walks through gene augmentation, gene editing (CRISPR), RNA therapy, stem-cell therapy, and optogenetics with step-by-step 3D visuals and a plain-language comparison.

Spotted something out of date? Use the report button in the footer of any page.